---
title: Additional Diabetes Treatment Options
---
# Additional Diabetes Treatment Options

## DPP-4 inhibitors (~0.5–1%)
* Block degrad. GLP-1 & GIP → ↑ insulin.
* ↑ risk of HF w/ saxagliptin (NEJM 2013;369:1317), not w/ others.
* > 參考➡️ [Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus](https://www.nejm.org/doi/full/10.1056/NEJMoa1307684)

## Sulfonylureas (SU) (~1.5%)
* ↑ insulin secretion. Hypoglycemia; wt gain.
* Thiazolidinediones (TZD) (~1%)
* ↑ insulin sens. in adipose & muscle. Wt ↑, fluid retention & CHF. Hepatox. ↑ MI w/ rosiglitazone? Contraindic. in HF & liver dysfxn.

## Glinides (~1%)
↑ insulin secretion; hypoglycemia; wt gain

## α-gluc. inhib (~0.5%)
↓ intestinal CHO absorption. Abd pain, flatulence.

## Pramlintide (~0.5%)
* Delays gastric emptying & ↓ glucagon. N/V
* Insulin
* (variable)
* ↓↓ glc; wt gain. Mandatory in T1D; consider in T2D if oral Rx inadeq. Weekly vs. daily w/ similar glycemic ctrl (NEJM 2020;383:2107).

## Tirzepatide (~2–2.5%)
* Dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist.
* Greater ↓ in A1C & wt vs. semaglutide (NEJM 2021;385:503).
> 參考➡️ [ Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519)
* Not yet FDA approved.

## Gastric bypass
Wt ↓↓↓; can cause remission DM (NEJM 2014;370:2002)
> 參考➡️ [Comment on: trends in utilization of bariatric surgery, 2010-2014: sleeve gastrectomy dominates](https://www.soard.org/article/S1550-7289\(17\)30051-5/abstract)

> Lifestyle changes including weight management are foundational. Diabetes Care 2022;45:S256; NEJM 2021; 385:896. NEJM 2019;381:1995; Lancet 2019;393:31; Circ 2019;139:2022; NEJM 2019;380:2295.
> 詳見[Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.](https://www.ncbi.nlm.nih.gov/pubmed/31535829)
> 參考➡️ [Canagliflozin and renal outcomes in type 2 diabetes and nephropathy](https://www.nejm.org/doi/full/10.1056/nejmoa1811744)
> 參考➡️ [Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes](https://www.nejm.org/doi/full/10.1056/NEJMoa2108269)


## Explain by ChatGPT


- DPP-4 inhibitors block the degradation of GLP-1 and GIP, which leads to an increase in insulin.
- There is an increased risk of HF with saxagliptin, but not with other DPP-4 inhibitors.
- Sulfonylureas increase insulin secretion. They can cause hypoglycemia and weight gain.
- Thiazolidinediones increase insulin sensitivity in adipose tissue and muscle. They can cause weight gain, fluid retention, and CHF. Hepatotoxicity is a concern with rosiglitazone. Thiazolidinediones are contraindicated in HF and liver dysfunction.
- Glinides increase insulin secretion and can cause hypoglycemia and weight gain.
- Alpha-glucosidase inhibitors decrease intestinal CHO absorption. They can cause abdominal pain and flatulence.
- Pramlintide delays gastric emptying and decreases glucagon. It can cause nausea and vomiting.
- Insulin can cause weight gain. It is mandatory in T1D; consider in T2D if oral Rx is inadequate.
- Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. It can cause a greater decrease in A1C and weight vs. semaglutide. It is not yet FDA approved.
- Gastric bypass surgery can cause a significant weight loss and can lead to remission of DM.

## 窩的英文不太好

- DPP-4 抑製劑阻斷 GLP-1 和 GIP 的降解，從而導致胰島素增加。
- 沙格列汀會增加心衰風險，但其他 DPP-4 抑製劑不會增加。
- 磺脲類藥物增加胰島素分泌。它們會導致低血糖和體重增加。
- 噻唑烷二酮增加脂肪組織和肌肉中的胰島素敏感性。它們會導致體重增加、體液瀦留和充血性心力衰竭。肝毒性是羅格列酮的一個問題。噻唑烷二酮類禁用於 HF 和肝功能障礙。
- 格列奈類藥物可增加胰島素分泌，可引起低血糖和體重增加。
- α-葡萄糖苷酶抑製劑會降低腸道對 CHO 的吸收。它們會引起腹痛和脹氣。
- 普蘭林肽延遲胃排空並降低胰高血糖素。它會引起噁心和嘔吐。
- 胰島素會導致體重增加。在 T1D 中是強制性的；如果口服 Rx 不充分，請考慮 T2D。
- Tirzepatide 是一種雙重葡萄糖依賴性促胰島素多肽-GLP-1 受體激動劑。與 semaglutide 相比，它可以導致 A1C 和體重的更大降低。它尚未獲得 FDA 批准。
- 胃繞道手術可導致體重顯著減輕，並可緩解 DM。

